Sugi Predict

Sugi Predict / Compounds / SCHEMBL14714802

SCHEMBL14714802

SCHEMBL14714802

COCc1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 12/20 0.61
▸ LIPG Q9Y5X9 12/20 0.61
▸ F11 P03951 2/20 0.57
▸ ESR2 Q92731 1/20 0.49
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ DGAT1 O75907 1/20 0.44
▸ CA12 O43570 1/20 0.42
▸ CA3 P07451 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ CA5A P35218 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CA5B Q9Y2D0 1/20 0.42
▸ SNCA P37840 1/20 0.41
▸ F2 P00734 1/20 0.41
▸ PRSS1 P07477 1/20 0.41
▸ PRSS2 P07478 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15579345 0.85 LPL (0.53) LPLLIPGF11ESR2CA1
SCHEMBL16382844 0.84 ESR2 (0.47) LPLLIPGF11ESR2CA1
SCHEMBL15602713 0.84 LPL (0.51) LPLLIPGF11ESR2CA1
SCHEMBL22028038 0.84 LPL (0.59) LPLLIPGF11ESR2CA1
SCHEMBL132390 0.84 LPL (0.59) LPLLIPGF11ESR2CA1
SCHEMBL13607260 0.84 LPL (0.59) LPLLIPGF11ESR2CA1
SCHEMBL27896905 0.82 LPL (0.43) LPLLIPGF11ESR2CA1
SCHEMBL3321210 0.82 LIPG (0.67) LPLLIPGF11ESR2CA1
SCHEMBL14790857 0.82 LPL (0.62) LPLLIPGF11ESR2CA1
SCHEMBL24776579 0.81 LPL (0.56) LPLLIPGF11ESR2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676927-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS Synnovation Therapeutics, Inc. (US) 2026-01-14 — — EP disclosed
EP-4637754-A2 SELECTIVE BET INHIBITORS AND USES THEREOF Tay Therapeutics Limited (GB) 2025-10-29 — — EP disclosed
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
WO-2024187049-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2024-09-12 — — WO disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
WO-2024138201-A2 SELECTIVE BET INHIBITORS AND USES THEREOF Tay Therapeutics Limited (GB) 2024-06-27 — — WO disclosed
WO-2023220671-A1 PRODRUGS USEFUL FOR REDUCING ANTHRACYCLINE CARDIOTOXICITY WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2023-11-16 — — WO disclosed
US-20230302162-A1 RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-09-28 — — US disclosed
US-11583596-B2 Radiolabeled Darapladib and analogs thereof and their use as imaging compounds INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-02-21 — — US disclosed
EP-4129978-A1 NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF Therabest Co., Ltd. (KR) 2023-02-08 — — EP disclosed
US-20150158827-A1 Process for the Synthesis of Triazoles MELINTA SUBSIDIARY CORP. 2015-06-11 — — US disclosed
US-8796465-B2 Process for the syntheses of triazoles MELINTA THERAPEUTICS, INC. (US) 2014-08-05 — — US disclosed
WO-2014043068-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2014-03-20 — — WO disclosed
US-20140031402-A1 Process for the Syntheses of Triazoles RIB-X PHARMACEUTICALS, INC. (US) 2014-01-30 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
US-8399660-B2 Process for the synthesis of triazoles RIB-X PHARMACEUTICALS, INC. (US) 2013-03-19 — — US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 — — EP disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC LPL 188/4885LIPG 197/4885F11 1953/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LPL 204/4885LIPG 148/4885F11 3200/4885
US-11583596-B2 Radiolabeled Darapladib and analogs thereof and their use as imaging compounds PLA2G4B, PLA2G1B, PLA2G12B LPL 86/4885LIPG 66/4885F11 3034/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 LPL 181/4885LIPG 384/4885F11 773/4885
US-20230302162-A1 RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS PLA2G4B, PLA2G1B, PLA2G12B LPL 86/4885LIPG 66/4885F11 3034/4885
US-20140031402-A1 Process for the Syntheses of Triazoles PROKR1, VIP, SI LPL 3740/4885LIPG 4099/4885F11 2911/4885
US-20150158827-A1 Process for the Synthesis of Triazoles PROKR1, SI, IL33 LPL 4214/4885LIPG 4244/4885F11 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.